---
title: "Atricure (ATRC) Receives a Buy from Stifel Nicolaus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293767885.md"
description: "Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Atricure (ATRC) with a $50 price target. Piper Sandler's Matthew O'Brien also issued a Buy rating today, while Oppenheimer maintained a Hold rating on the stock."
datetime: "2026-07-24T13:55:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293767885.md)
  - [en](https://longbridge.com/en/news/293767885.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293767885.md)
---

# Atricure (ATRC) Receives a Buy from Stifel Nicolaus

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Atricure, with a price target of $50.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Wise covers the Healthcare sector, focusing on stocks such as Solventum Corporation, Atricure, and Boston Scientific. According to TipRanks, Wise has an average return of \-2.5% and a 45.20% success rate on recommended stocks.

In addition to Stifel Nicolaus, Atricure also received a Buy from Piper Sandler’s Matthew O’Brien in a report issued today. However, on the same day, Oppenheimer maintained a Hold rating on Atricure (NASDAQ: ATRC).

### Related Stocks

- [ATRC.US](https://longbridge.com/en/quote/ATRC.US.md)
- [SOLV.US](https://longbridge.com/en/quote/SOLV.US.md)
- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)

## Related News & Research

- [Atricure Still Faces Broad, Evolving Risks Despite No Material Changes in 2025 10-K Disclosures](https://longbridge.com/en/news/294017350.md)
- [Board Member At AtriCure Exercises Options Worth $491K](https://longbridge.com/en/news/294530665.md)
- [AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares](https://longbridge.com/en/news/294417197.md)
- [AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year](https://longbridge.com/en/news/293959967.md)
- [AtriCure to join Needham Virtual MedTech & Diagnostics investor conference](https://longbridge.com/en/news/293928171.md)